Zealand Pharma Shares Fall Amid Resurfaced Concerns Over Drug Trial Dropout Rates
Zealand Pharma's shares declined significantly as data revealed that nearly one in five patients discontinued the late-stage survodutide trial for obesity due to gastrointestinal side effects. These high dropout rates are reigniting investor concerns.
Nearly one in five patients discontinued Zealand Pharma’s OMXCOP:ZEAL late-stage survodutide trial because of gastrointestinal side effects linked to the obesity drug, data released on Thursday showed, renewing investor concern over the high dropout rates. The Danish drugmaker’s shares fell as much as 13…